Cesca Therapeutics Inc. (KOOL: Quote), an autologous cell-based regenerative medicine company, announced that it priced an underwritten public offering of 7.53 million Units, consisting of an aggregate of 7.53 million shares of the Company's common stock and warrants to purchase 2.26 million shares of the Company's common stock, at a price of $1.50 per Unit.
Each warrant entitles the holder to purchase 0.30 of a share of common stock. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance.
The shares of common stock and warrants comprising the Units are immediately separable. All of the Units in the offering are being sold by Cesca.
The gross proceeds to Cesca from this offering are expected to be approximately $11.3 million, excluding any future proceeds from the potential exercise of the warrants and before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cesca.
The offering is expected to close on or about June 18, 2014, subject to the satisfaction of customary closing conditions.
Click here to receive FREE breaking news email alerts for ThermoGenesis Corp. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com